Innovent Biologics, Inc. (IVBXF)
Market Closed
3 Jun, 16:33
OTC PINK 
$
10. 24
-0.19
-1.83%
$
17.95B Market Cap
- P/E Ratio
- Div Yield
954 Volume
0 Eps
$ 10.43
Previous Close Want to track IVBXF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
IVBXF closed today lower at $10.24, a decrease of -1.83% from yesterday's close, completing a monthly decrease of -9% or -$1.01. Over the past 12 months, IVBXF stock lost -0.65%.
IVBXF is not paying dividends to its shareholders.
The last earnings report, released on Apr 01, 2026, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.01%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on HKEX (HKD).
Innovent Biologics, Inc. (IVBXF) FAQ
What is the stock price today?
The current price is $10.24.
On which exchange is it traded?
Innovent Biologics, Inc. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is IVBXF.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 17.95B.
Has Innovent Biologics, Inc. ever had a stock split?
No, there has never been a stock split.
Innovent Biologics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. De-Chao Yu Ph.D. CEO | OTC PINK Exchange | KYG4818G1010 ISIN |
| US Country | 7,502 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Innovent Biologics, Inc. is an innovative biopharmaceutical company focusing on developing and commercializing a broad range of monoclonal antibodies and other therapeutic drug assets. Their primary focus areas include oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases. With its foundation laid in 2011, Innovent Biologics has been dedicated to addressing the unmet medical needs in the People's Republic of China. Headquartered in Suzhou, the company has established a strong footing in the healthcare industry through its extensive product portfolio and ongoing research and development efforts.
Products and Services
Innovent Biologics provides an extensive array of products and services aimed at improving patient care and treatment outcomes. Here is a closer look at their offerings:
- Tyvyt: A human anti-PD-1 monoclonal antibody designed for cancer treatment.
- BYVASDA: A fully-human anti-VEGF monoclonal antibody aimed at inhibiting angiogenesis in various diseases.
- HALPRYZA: A recombinant chimeric murine/human anti-CD20 monoclonal antibody for treating hematologic malignancies.
- SULINNO: A fully-human antiTNF-a monoclonal antibody, used in autoimmune diseases like rheumatoid arthritis.
- Pemazyre: A selective FGFR inhibitor that targets specific fibroblast growth factor receptors involved in cancer development.
- Olverembatinib: A novel BCR-ABL tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
- Cyramza: A VEGF receptor 2 antagonist that plays a role in cancer treatment by inhibiting tumor angiogenesis.
- Retsevmo: A selective and potent RET kinase inhibitor used in treating cancers with RET mutations.
- In addition to marketed products, Innovent Biologics has an expansive pipeline of developing treatments, including:
- IBI-326: A fully-human BCMA CAR T-cell therapy targeting multiple myeloma.
- IBI-376: An oral inhibitor of PI3Kd that holds potential in treating hematologic malignancies.
- IBI-351: A KRASG12C inhibitor being developed for specific types of cancer.
- IBI-344: Targets silencing 1/TRK tyrosine kinase in cancer treatments.
- IBI-126: An ADC targeting CEACAM5 for colorectal cancer treatment.
- IBI-306: A novel monoclonal antibody against proprotein convertase subtilisin/kexin type 9 enzyme, potential in treating hypercholesterolemia.
- IBI-362: A glucagon-like peptide-1 receptor/glucagon receptor dual agonist for diabetes management.
- IBI-112: A novel long-acting anti-IL-23 for autoimmune diseases.
- The company also focuses on novel immunotherapy and targeted therapy options, including IBI-110 (novel anti-LAG3), IBI-939 (novel anti-TIGIT), and others aiming to enhance oncology treatment modalities.
- Furthermore, Innovent offers distribution services for pharmaceutical products, alongside providing consultation, and advanced research and development services to foster innovation and address diverse therapeutic areas.
Contact Information
Address: 168 Dongping Street, Suzhou, China, 215123
Phone: 86 512 6956 6088
Website: https://www.innoventbio.com
